Investigating the clinical efficacy of cevimeline in improving the symptoms of primary sjogren syndrome: a randomized controlled trial.

Investigating the clinical efficacy of cevimeline in improving the symptoms of primary sjogren syndrome

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033420

Enrollment

Unknown

Registered

2020-05-31

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sj?gren Syndrome

Interventions

experimental group:Cevimeline

Control Group:placebo

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) meet a criterion of American-European Consensus Group(AECG2002); (2) no respiratory, cardiovascular, digestive system disease or the disease condition is stabilized after treatment.

Exclusion criteria

Exclusion criteria: (1) a history of use of M choline receptor agonists and cytochrome drugs for nearly a month; (2) having mental disease; (3) being pregnancy or lactation; (4) combined with other autoimmune disease.

Design outcomes

Primary

Measure	Time frame
Saliva secretion;Lacrimal secretion;	—

Countries

China

Contacts

Public ContactShengming Wang

The Affiliated Huai'an Hospital of Xuzhou Medical University

wangshengming5191@dingtalk.com+86 15061225191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026